Whittier Trust Co. of Nevada Inc. Acquires 14,172 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Whittier Trust Co. of Nevada Inc. boosted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 157.3% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 23,180 shares of the medical equipment provider’s stock after buying an additional 14,172 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in Intuitive Surgical were worth $11,387,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. NBC Securities Inc. raised its holdings in Intuitive Surgical by 34.4% during the 1st quarter. NBC Securities Inc. now owns 121 shares of the medical equipment provider’s stock worth $48,000 after purchasing an additional 31 shares during the last quarter. &PARTNERS bought a new position in shares of Intuitive Surgical during the 1st quarter worth approximately $293,000. International Assets Investment Management LLC boosted its holdings in shares of Intuitive Surgical by 9.7% during the 1st quarter. International Assets Investment Management LLC now owns 2,234 shares of the medical equipment provider’s stock worth $882,000 after buying an additional 198 shares in the last quarter. Cooper Financial Group acquired a new stake in shares of Intuitive Surgical during the 1st quarter worth approximately $230,000. Finally, Ballentine Partners LLC increased its stake in shares of Intuitive Surgical by 13.3% in the 1st quarter. Ballentine Partners LLC now owns 3,236 shares of the medical equipment provider’s stock valued at $1,291,000 after acquiring an additional 379 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Analyst Ratings Changes

ISRG has been the subject of a number of research reports. Raymond James raised their price target on shares of Intuitive Surgical from $500.00 to $540.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. Morgan Stanley boosted their target price on Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Mizuho increased their price target on Intuitive Surgical from $440.00 to $500.00 in a report on Thursday. Royal Bank of Canada boosted their price objective on Intuitive Surgical from $525.00 to $555.00 and gave the company an “outperform” rating in a report on Friday. Finally, Evercore ISI reiterated a “cautious” rating on shares of Intuitive Surgical in a report on Friday. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, Intuitive Surgical has an average rating of “Moderate Buy” and a consensus price target of $513.74.

Intuitive Surgical Stock Performance

ISRG stock traded down $1.02 during midday trading on Monday, reaching $520.13. 874,800 shares of the company’s stock traded hands, compared to its average volume of 1,475,606. The firm has a market capitalization of $184.49 billion, a PE ratio of 94.07, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $523.34. The company has a 50-day moving average price of $483.85 and a two-hundred day moving average price of $438.56.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter last year, the company earned $1.18 EPS. The firm’s revenue was up 14.5% compared to the same quarter last year. As a group, analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Insider Activity

In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total value of $19,591,902.12. Following the sale, the senior vice president now directly owns 3,001 shares in the company, valued at $1,461,006.84. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Intuitive Surgical news, insider Mark Brosius sold 2,115 shares of Intuitive Surgical stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the completion of the sale, the insider now directly owns 295 shares in the company, valued at $145,113.45. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the sale, the senior vice president now owns 3,001 shares in the company, valued at approximately $1,461,006.84. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 53,120 shares of company stock worth $25,528,753. 0.90% of the stock is owned by company insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.